Project aims to develop an integrated, patient-centred, affordable and sustainable system for proactive management of patients undergoing peritoneal dialysis based on patients’ needs using innovative technologies and methodologies for service design Methods This is an observational cohort study which aims to develop a user-friendly and functional IT supported system for education and monitoring of patients undergoing peritoneal dialysis in their homes. We intend to collect information on physiological measures through different sensors in order to be able to compare and ascertain which methods are most acceptable to patients and providers. Study sites Postgraduate Institute of Medical Education and Research, Chandigarh and Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow. Current status The prototype Mobile Application is being tested

p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 15.0px Times; color: #323333; -webkit-text-stroke: #323333} p.p2 {margin: 0.0px 0.0px 0.0px 0.0px; font: 18.0px Arial; color: #323333; -webkit-text-stroke: #323333} span.s1 {font-kerning: none} span.s2 {text-decoration: underline ; font-kerning: none; color: #772583; -webkit-text-stroke: 0px #772583} span.s3 {font: 14.0px Calibri; font-kerning: none; color: #000000; -webkit-text-stroke: 0px #000000} span.s4 {font: 13.0px Calibri; font-kerning: none} span.s5 {font: 9.0px 'Times New Roman'; font-kerning: none} Fluid administration is a fundamental component of the management of critically ill patients and the choice of fluid is a longstanding issue of debate. Worldwide, 0.9% saline has traditionally been the most widely used resuscitation fluid, however its use is increasingly challenged by evidence that suggests its high chloride content may have clinically important adverse effects. Two pivotal George Institute trials, the Saline versus Albumin

A prospective, multicentre, parallel group, concealed, blinded, randomised controlled trial in critically ill mechanically-ventilated adults. The aim is: To determine whether the administration of placebo (daily administration of 10 ml 0.9% saline IV) is non-inferior to standard practice (daily administration of pantoprazole 40 mg IV) when judged by the incidence of clinically important gastrointestinal (GI) bleeding?  To determine whether the administration of placebo (daily administration of 10 ml 0.9% saline IV) is superior to standard practice (daily administration of pantoprazole 40 mg IV) as it results in a reduction in net harm by reducing the incidence of serious infectious complications (ventilator-associated pneumonia and Clostridium difficile infection) and therefore "downstream" harms when measured as duration of mechanical ventilation, intensive care unit (ICU) and hospital length of stay, and 90-day mortality? 

Chronic kidney disease (CKD) has become a growing public health problem worldwide with a serious socio-economic impact. CKD results in mortality due to progression to end-stage renal disease and a disproportionate increase in the risk of cardiovascular disease (CVD) and associated deaths. Recent advances suggest the possibility of using biologically relevant biomarkers to develop prediction algorithms for outcomes in patients with CKD. However, there are no large longitudinal studies comparing the differences in racially, geographically and genetically different populations. Aim: Project aims to establish a large cohort of Indian patients with moderate kidney failure (40-60% reduction in kidney function) by enrolling 5000 patients cared for at 8 centers nationwide, who will be prospectively followed for a minimum of five years and to develop prediction algorithms. It will be the first study to evaluate the prediction power of biologically important biomarkers on clinically relevant end

Healthcare associated infections (HAI) cause significant and life-threatening harm to patients and incur major additional costs. Patients with kidney disease are especially susceptible to HAI, due to the harm associated with central dialysis catheter use. These catheters, essential to the delivery of life-sustaining dialysis treatment, are widely used and are a major driver of bloodstream infection and increased mortality seen in patients receiving dialysis. The REDUCCTION Partnership Project has the following aims: To define the national, clinical and economic burden of dialysis catheter infections in Australia and New Zealand To implement an evidence-based and systematic intervention package using a stepped-wedge cluster design with the objective of reducing dialysis catheter-related bacteraemia. To establish a framework for monitoring dialysis catheter-related bacteraemia and sustaining improvements from the intervention phase. Current status: Data collection for our primary analysis i

One of the 12 key priorities that the New South Wales government has committed to is reducing overweight and obesity rates of children by five percent over 10 years. This project aims to estimate the costs associated with achieving this target.